Sildenafil improves the alveolar-capillary function in heart failure patients

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Sildenafil is utilized for pulmonary hypertension and is considered safe for patients with chronic heart failure (HF).
• Chronic HF is associated with impaired lung mechanics and gas diffusion.

Purpose of the Study:

• To assess sildenafil's impact on lung mechanics, gas diffusion, and exhaled nitric oxide (eNO) at rest and during exercise in chronic HF patients.
• To determine if sildenafil can prevent exercise-induced pulmonary edema in this population.

Main Methods:

• A randomized study involving 22 male chronic HF patients.
• Measurements included lung diffusion capacity for carbon monoxide (DLCO), molecular diffusion (DM), pulmonary capillary volume (VC), and eNO at rest and during exercise.
• Evaluations were conducted after single doses of placebo, 25 mg sildenafil, and 100 mg sildenafil, alongside maximal cardiopulmonary exercise testing.

Main Results:

• Sildenafil significantly improved resting pulmonary mechanics and DLCO in a dose-dependent manner.
• The 100 mg dose of sildenafil appeared to prevent exercise-induced pulmonary edema.
• Peak oxygen uptake (Peak VO2) increased significantly with sildenafil, correlating with DLCO improvements.

Conclusions:

• Sildenafil enhances exercise performance in chronic HF patients.
• The drug improves lung mechanics and gas diffusion, likely by modulating nitric oxide pathways.
• Sildenafil demonstrates potential in preventing exercise-induced pulmonary edema in chronic heart failure.